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Nicotine has remarkably diverse effects on the brain. Being the main active compound in
tobacco, nicotine can aversively affect brain development. However, it has the ability to
act positively by restoring attentional capabilities in smokers. Here, we focus on nicotine
exposure during the prenatal and adolescent developmental periods and specifically, we
will review the long-lasting effects of nicotine on attention, both in humans and animal
models. We discuss the reciprocal relation of the beneficial effects of nicotine, improving
attention in smokers and in patients with neuropsychiatric diseases, such as schizophrenia
and attention deficit/hyperactivity disorder, vs. nicotine-related attention deficits already
caused during adolescence. Given the need for research on the mechanisms of nicotine’s
cognitive actions, we discuss some of the recent work performed in animals.
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INTRODUCTION
Smoking is the leading preventable cause of death and disability
in the USA (Novick, 2000), and nicotine, the main active com-
pound in tobacco smoke can have health effects in very different
ways. Obviously, the best known is its highly addictive property.
In addition, it has various more subtle effects on the brain. Two
prominent features are its effect on brain developmental and on
attention. Moreover, nicotine has been shown to exert a pro-
tective effect on the display of neurodegenerative diseases. The
mechanisms behind the adverse and potentially beneficial effects
will need more research in the years to come. This review will
highlight some of the salient features of nicotine along these
lines.
With respect to development, there are two main develop-
mental periods during which individuals are at risk to come into
contact with biologically relevant doses of nicotine. The first win-
dow of vulnerability is during prenatal development, when women
might smoke during pregnancy. The second is the developmen-
tal period of adolescence, during which when most smokers start
their habit (Chassin et al., 1996). In adulthood the effects of nico-
tine may be less on neuronal development, but become apparent
in its acute effects on neuronal circuitry properties (for review
Poorthuis et al., 2009). This has immediate consequences for the
attention state of the brain (for review Counotte et al., 2011b).
Related to this, smokers use nicotine to self-medicate their atten-
tion deficits (Lerman et al., 2001), and patients with attention
deficit/hyperactivity disorder (ADHD) perform worse when absti-
nent from nicotine (McClernon et al., 2008). ADHD is a common
clinically significant condition in school-aged children, affecting
5–10% of children worldwide, with persisting lifelong features
(Pediatrics, 2000). There are reciprocal links between smoking and
ADHD, with on one hand nicotine exposure during development
increasing the risk for ADHD, and on the other hand high rates
of ADHD patients that are smokers, probably (at least partly)
to alleviate their attention deficits. Thus, despite negative effects
of nicotine on brain development and its persistent addictive
properties, there are instances in which nicotine exposure can be
beneficial for an individual.
Another interesting feature of nicotine is its reported long-term
benefit in protection to neurodegenerative disease (Bordia et al.,
2008; Echeverria et al., 2010, for review, see Shimohama, 2009).
Both nicotine and its breakdown product cotinine have been
suggested as cognitive enhancers for Parkinson’s and Alzheimer’s
disease in preclinical models (Bordia et al., 2008; Echeverria et al.,
2010). Although potentially of interest, this aspect of nicotine
action will not be discussed further here.
In this review, we will examine the long-term effects of nico-
tine exposure during two epochs of brain development (prenatal
and peri-adolescent) in the attention domain of cognition. In
humans, it is difficult to separate the effects of developmental
nicotine exposure from confounding factors, such as demograph-
ics and pre-existing or co-morbid psychiatric disorders, which is
why we will also review studies using animal models of devel-
opmental nicotine exposure. As recent studies have established a
correlation of developmental nicotine use and attention, and stud-
ies describing the mechanisms behind these effects start to emerge,
we will focus on studies assessing attention performance. Recent
work using animal models has enabled us to study the molecu-
lar and synaptic mechanisms underlying the long-term effects of
developmental nicotine exposure.
PRENATAL NICOTINE EXPOSURE
Even though smoking by pregnant women is declining in recent
years, still 13% of women reported smoking during pregnancy in
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2005 (Center for Disease Control and Prevention, 2009), which
might even be an underestimation due to non-disclosure (Dietz
et al., 2010). In some high-risk populations, smoking rates are
as high as 25% (Arria et al., 2006). Many women find it hard
to quit smoking when they are pregnant (Einarson and Rior-
dan, 2009). Recommending nicotine replacement therapy may
not be beneficial (Slotkin, 2008) considering that nicotine can
cross the placenta and thus will enter the fetus through the
mother’s circulation. The developing fetus does not have the
abilities to breakdown nicotine and its active metabolite coti-
nine as efficient as adults do, so nicotine and cotinine levels
will buildup in the fetus (Sastry et al., 1998). A well-known
more immediate consequence of maternal smoking during preg-
nancy is the increased risk for sudden infant death syndrome
due to nicotine targeting monoamine pathways in brainstem
and cardiac sympathetic innervation (Slotkin et al., 1999, 2010),
and intra-uterine growth retardation resulting in reduced birth
weight (Ernst et al., 2001b). Although it does not outweigh
the negative effects of smoking, smoking during (late) preg-
nancy could protect the mother from hypertension and result-
ing pre-eclampsia (England and Zhang, 2007; Wikstrom et al.,
2010).
PRENATAL NICOTINE EXPOSURE AND DEVELOPMENT OF ADHD
There is a substantial body of literature of both retrospective
population-based studies and case-control studies suggesting that
prenatal nicotine exposure is associated with an increased occur-
rence of ADHD (Milberger et al., 1996; Thapar et al., 2003; Schmitz
et al., 2006; Biederman et al., 2009; Galera et al., 2011; Sagiv et al.,
2012; for review Winzer-Serhan, 2008; Cornelius and Day, 2009).
Milberger et al. (1996) found a 2.7-fold increase in ADHD asso-
ciated with maternal smoking, when comparing 140 boys with
ADHD to 120 control boys and their first-degree biological rel-
atives. Galera et al. (2011) found that prenatal tobacco exposure
has a risk factor of 1.41 for attention deficits and impulsivity in a
longitudinal cohort of 2057 individuals who were followed from
5 months of age to 8 years. Already shortly after birth, infants
exposed to tobacco smoking in utero showed poorer attention
skills (Espy et al., 2011). In patients with ADHD, heavy maternal
smoking is associated with poorer performance on the contin-
uous performance task (CPT; Motlagh et al., 2011). However, a
causal link between maternal smoking and ADHD has not been
established. Using a different experimental design examining 815
families in which infants were divided into two groups, one group
that was genetically related to their parents, and one that was genet-
ically unrelated to their mothers because of fertility treatments
that used donor eggs, Thapar et al. (2009) found that ADHD
was only related to maternal smoking in the genetically related
infants, even though confounding factors (like parental ADHD)
were controlled for. In the genetically unrelated infants, maternal
smoking did lead to a decreased birth weight, but was not asso-
ciated with ADHD, suggesting that in traditional observational
designs it is impossible to adequately control for confounding fac-
tors. This also suggests that the link between maternal smoking
and ADHD might be more complicated, involving the interaction
of genetic vulnerability and environmental influences including
nicotine exposure.
PRENATAL NICOTINE AND GENE× ENVIRONMENT INTERACTIONS
EXPLORED IN ANIMAL RESEARCH
A way to have better control over confounding factors and complex
gene× environment interactions in humans is to use an animal
model. Importantly, nicotine in rodents was found to have similar
rewarding properties and cognitive effects to humans. This makes
rodent nicotine research to large extent valid to in translating to
human brain development, addictive properties, and attention.
Prenatal exposure to nicotine in rodents has been shown to
modulate normal developmental activation of nAChRs, which is
of importance for cell survival, synapse formation, and synapse
maturation (for review Dwyer et al., 2009). Rats that had been
previously exposed to nicotine in utero, in a paradigm where moth-
ers were exposed to 0.06 mg/ml nicotine in the drinking water
before and during pregnancy, show impairments in attention per-
formance in the 5-CSRTT, both when tested during adolescence
and adulthood (Schneider et al., 2011, 2012). Specifically, ani-
mals tested as adults showed decreased correct responses and an
increased number of omissions (not paying attention; Schneider
et al., 2011). Animals tested during adolescence only showed an
increase in anticipatory responses but no difference in accuracy
(Schneider et al., 2012). Also, prenatal nicotine exposure caused
increased motor impulsivity in adult animals, indicated by the
increased number of anticipatory responses, but it did not cause
an increase in impulsive choice, since there was no difference in
delay-discounting (Schneider et al., 2011). In addition, in a par-
adigm modeling third trimester nicotine exposure, where pups
were exposed to 6 mg/kg nicotine per day by gastric intubation
from P1 to P7, it was confirmed that this did not lead to differ-
ences in impulsive choice, and similarly, there were no differences
in risky decision-making (Mitchell et al., 2012). Together, these
findings show that prenatal nicotine exposure does lead to atten-
tion deficits, but animals show only some of the cognitive deficits
(e.g., impulsive action) that are observed in humans. This suggests
that some deficits may be due to human-specific genetic or envi-
ronmental factors, or are due to other components than nicotine
in tobacco smoke (Baker et al., 2004).
ADOLESCENT NICOTINE EXPOSURE
Brain development continues during adolescence, and nicotine
from tobacco smoke can interfere with normal development (for
review Slotkin et al., 2007; Counotte et al., 2011b), thus lead-
ing to deficits in attention and impulsivity. Jacobsen et al. (2005,
2007) showed that adolescent smokers perform worse on work-
ing memory and attention tasks. Individuals who were exposed
to prenatal maternal smoking were even more severely impaired
than those that were not (Jacobsen et al., 2007). Similarly, there
were gender differences; female adolescent smokers were impaired
on both a visual and auditory attention task, whereas male ado-
lescent smokers were only impaired on the auditory attention task
(Jacobsen et al., 2007). It is important to note that the smokers
were allowed to smoke during a break between the tests to make
sure they were not inattentive because of withdrawal from nicotine
(West and Hack,1991). These deficits in attention are accompanied
by reduced attention-associated prefrontal cortical blood-oxygen
level dependent (BOLD)-responses (Musso et al., 2007), indicating
the importance of the prefrontal cortex in attention.
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Smokers in general have been reported to have higher levels of
impulsivity, both impulsive choice (Bickel et al., 1999; Mitchell,
1999) and impulsive action, or inhibitory control (Mitchell, 1999;
Spinella, 2002; Skinner et al., 2004). However, it is difficult to
determine whether nicotine exposure leads to impulsivity, or that
impulsivity leads people to start smoking. There is currently no
data showing that adolescent smokers have increased impulsivity
or that adolescent nicotine exposure has long-lasting effects on
impulsivity.
To address the issue of causality, we used an animal model
to study the long-term effect of adolescent nicotine exposure on
attention and impulsivity and found that 10 days of adolescent
nicotine exposure (three daily injections of 0.4 mg/kg) impairs
attention in the 5-CSRTT in adult animals, even after a relatively
long nicotine-free period (Counotte et al., 2009, 2011a). Also, these
animals showed increased motor impulsivity, indicated by an ele-
vated number of premature responses in the 5-CSRTT but no
deficits in impulsive choice (Counotte et al., 2009). We found that
the decrease in attention following adolescent nicotine exposure
was (at least in part) caused by a decreased synaptic expression
of the metabotropic glutamate receptor mGluR2 in the medial
prefrontal cortex, because stimulation of this receptor by local
infusion of an mGluR2/3 agonist relieved the attention deficits
and brought the adolescent nicotine exposed animals back to the
level of their control counterparts (Counotte et al., 2011a). This
change in mGluR2 signaling in the mPFC in turn leads to an alter-
ation of the rules for spike timing-dependent plasticity, meaning
that the ability to filter information has decreased (Goriounova
and Mansvelder, 2012). Thus, adolescent nicotine exposure affects
synaptic signaling mechanisms involving metabotropic glutamate
signaling in the mPFC. These signaling mechanisms are known
to be important for plasticity and synaptic maturation (Michalon
et al., 2012).
BENEFICIAL EFFECTS OF NICOTINE-LIKE SUBSTANCES
Nicotine has complex effects on cognitive performance that are
in part determined by the existing state of the cholinergic sys-
tem and by signaling via nicotinic receptors. Smokers, healthy
non-smokers, and patients with impaired prefrontal cortical func-
tion, all differ in to what extent nicotine affects their cognitive
performance. In healthy subjects, nicotine has no or only weak
effects on cognitive performance. However, subjects with subop-
timal performance, such as patients with ADHD, schizophrenia,
or Alzheimer’s disease are more likely to benefit from nicotine,
and nicotinic drugs can act beneficial on attention and sensory
gating (Newhouse et al., 2004). Compared with the percentage of
smokers in the general population [currently around 20% in the
US (Services and U. S. Department of Health and Human Ser-
vices, 2010), a higher percentage of mentally ill patients smoke
regularly (26–88%, depending on the mental illness; Lasser et al.,
2000)]. Particularly patients with schizophrenia, depression, post-
traumatic stress disorder, or ADHD smoke, and they have a
lower chance of quitting smoking (Lambert and Hartsough, 1998;
Services and U. S. Department of Health and Human Services,
2010). It has been postulated that tobacco smoking may amelio-
rate some of the major cognitive deficits in mentally ill patients
and may act as self-medication (Lerman et al., 2001; Newhouse
et al., 2004). On the other hand, abstinence worsens performance
on attention tasks such as the human CPT in ADHD patients,
but not in controls (McClernon et al., 2008). In healthy non-
smokers the evidence of beneficial effects from nicotine on cog-
nition is less clear. Performance in some cognitive tasks shows
improvement by nicotine, whereas other aspects of cognition are
impaired (Levin et al., 1997, 1998; Ernst et al., 2001a; Wignall
and de Wit, 2011). For example, in non-smokers, nicotine can
lead to faster reaction times in attention and working memory
tasks, although this improvement might come at the expense of
fewer correct responses (Le Houezec et al., 1994; Foulds et al.,
1996). It is of note that even in smokers, the presence of nico-
tine may not necessarily improve their attention to the levels of
their non-smoking counterparts. In a study by Jacobsen et al.
(2007) adolescent smokers were allowed to smoke during a mid-
way break on an attention task, and they still performed worse
than non-smokers.
The dichotomy in the beneficial effects of nicotine and related
compounds is probably due to alterations in the cholinergic and/or
cortical attention system of smokers and patients with distinct psy-
chiatric diseases. Various factors maybe causing this. For instance,
it might relate to some extent to smoking-induced changes in
nicotinic receptor number and sensitivity (Kadir et al., 2006; Bra-
sic et al., 2012), or alternatively, disease-specific developmental
disturbances in receptor expression or aberrant development of
circuitry may underlie this.
In smokers, whose nicotinic acetylcholine receptor signaling
pathways have undergone adaptations due to chronic nicotine
exposure, nicotine can be beneficial for attention performance.
However, this beneficial effect of nicotine is in the context of
generally impaired attention and cognitive ability after nicotine
deprivation (Kleykamp et al., 2011; Vossel et al., 2011). In fact,
the effect of nicotine, as that of many other drugs, resembles
an inverted U-shape function in which subjects who perform at
suboptimum levels will show increased performance after drug
stimulation (Newhouse et al., 2011). Thus, smoking or nico-
tine administration in nicotine-dependent smokers only reverses
the impairment in cognitive function caused by abstinence from
smoking (Sacco et al., 2004).
This difference in altered state of nicotine sensitive pathways
is reflected in studies in which compounds, directly or indirectly
targeting nAChRs, are tested in (pre)clinical trials for their cogni-
tive enhancing effects. One of these, AZD3480/TC1734, a partial
agonist of α4β2∗ nAChR, exhibits memory-enhancing proper-
ties in healthy rodents and man (Obinu et al., 2002; Dunbar
et al., 2007), albeit with mixed results in different patient pop-
ulations (Dunbar et al., 2011; Frolich et al., 2011; Velligan et al.,
2012). Despite initial positive reports on the effects in a phase
II clinical trial, in which AZD3480 seemingly improved symp-
toms of ADHD, as well as results on the Stop Signal Reaction
task, no further publication has yet appeared. In rats however,
AZD3480 has been shown to improve MK801-induced impair-
ments in accuracy as measured in an operant signal detection task,
without having an effect on its own (Rezvani et al., 2012). Thus,
novel drugs targeting the nicotinic receptors might have benefi-
cial effects in a brain in which cholinergic signaling is disturbed
(Figure 1).
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FIGURE 1 | Nicotine exposure during prenatal and/or adolescent
development has long-lasting detrimental effects on attention, even
after prolonged abstinence. Exposure during both developmental periods
(dark gray) has additive effects leading to worse performance than healthy
controls (open, hatched line) during adulthood. Patients with certain
psychiatric disorders (e.g., ADHD, schizophrenia; light gray) also suffer from
decreased attention performance. Nicotine has beneficial effects on attention,
but only in those individuals who have decreased levels of attention to begin
with, like smokers (Lawrence et al., 2002) and patient populations (Lerman
et al., 2001; Newhouse et al., 2004), but not in healthy controls (hatched line;
Levin et al., 1997, 1998; Wignall and de Wit, 2011), albeit that nicotine is not
always beneficial for smokers (Jacobsen et al., 2005, 2007).
FUTURE PERSPECTIVES
Nicotine acts in the brain via a complex repertoire of receptor
subtypes. Not surprisingly, many of the precise underlying mech-
anisms of action of nicotine on cognitive function still need to
be revealed. Experimental work on animal models might assist
in this.
Results from clinical and preclinical studies show that efficacy
of nicotinic receptor targeting drugs could in principle be pro-
foundly influenced by differences in the state of the cholinergic
system and/or that of the involved circuitry, and hence possibly the
health or disease status of the individual. Nicotinic-compounds
are promising as cognitive enhancers, and most likely act only
in patients. This has the consequence that the type of animal
model used to screen treatment efficacy should well fit the disease
state targeted. Modeling such a state at the preclinical level can
be achieved with genetic alterations, or by using pharmacological
agents. Nicotine exposure during specific developmental periods
maybe one of these, thereby assuring that stable alterations in
receptor levels or signaling state of patients is mimicked. In addi-
tion, studying animals carrying human gene mutations offers the
possibility of specifically addressing the functional role in behav-
ioral output related to the human disease (Trueman et al., 2012).
Moreover, it should be noted that “cognitive improvement” is a
broad concept, and that preclinical models should try to address
a large panel of behavioral phenotypes, including altered states
of attentional performance, which are in general more difficult to
address. Current improvements in technology and animal behav-
ioral paradigms hold a promise for the further mechanistic under-
standing of the effects of nicotine on the brain (Endo et al., 2011;
Winter and Schaefers, 2011).
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